Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

(2021) Maciej Banach et al.   PHARMACOLOGICAL RESEARCH

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

(2020) Jan Borén et al.   EUROPEAN HEART JOURNAL

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

(2020) Vera A. Bittner et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options

(2020) Andreja Rehberger Likozar et al.   ANNALS OF MEDICINE

Statin therapy increases lipoprotein(a) levels

(2019) Sotirios Tsimikas et al.   EUROPEAN HEART JOURNAL

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   ATHEROSCLEROSIS

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

(2019) Kausik K Ray et al.   Lancet Diabetes & Endocrinology

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials

(2017) Konstantinos C Koskinas et al.   EUROPEAN HEART JOURNAL

PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis

(2017) Alessandro Squizzato et al.   Internal and Emergency Medicine

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction

(2017) Maria-Corina Serban et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention

(2017) Erin A. Bohula et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of residual risk after statin therapy

(2016) Christina Reith et al.   ATHEROSCLEROSIS

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey

(2016) Ž. Reiner et al.   ATHEROSCLEROSIS

Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction

(2016) Takayuki Mitsuda et al.   HEART AND VESSELS

PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia

(2015) Rutger Verbeek et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials

(2012) Doralisa Morrone et al.   ATHEROSCLEROSIS